CHChristopher J. Handley

Christopher J. Handley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher J. Handley has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Mirna Z. Ilic

    School of Human Biosciences, La Trobe University, Melbourne, Victoria, Australia

    4 shared publications
  • H.Clem Robinson

    Department of Biochemistry and Molecular Biology, Monash University, Victoria 3800, Australia

    2 shared publications
  • Jacqueline M. Ross

    Department of Anatomy with Radiology, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand

    2 shared publications
  • Mirna Z Ilic

    School of Human Biosciences, La Trobe University, Melbourne, Victoria 3086, Australia

    2 shared publications
  • Tom Samiric

    School of Human Biosciences, La Trobe University, Melbourne, Victoria, Australia

    2 shared publications
  • Angus M. Tester

    Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia

    1 shared publication

Latest Publications

  • Open Access

    Efficacy of intra‐articular hyaluronan (Synvisc®) for the treatment of osteoarthritis affecting the first metatarsophalangeal joint of the foot (hallux limitus): study protocol for a randomised placebo controlled trial

    by Shannon E Munteanu, Hylton B Menz, Gerard V Zammit, Karl B Landorf, Christopher J Handley, Ayman ElZarka, Jason DeLuca

    Background: Osteoarthritis of the first metatarsophalangeal joint (MPJ) of the foot, termed hallux limitus, is common and painful. Numerous non‐surgical interventions have been proposed for this disorder, however there is limited evidence for their efficacy. Intra‐articular injections of hyaluronan have shown beneficial effects in case‐series and clinical trials for the treatment of osteoarthritis of the first metatarsophalangeal joint. However, no study has evaluated the efficacy of this form of treatment using a randomised placebo controlled trial. This article describes the design of a randomised placebo controlled trial to evaluate the efficacy of intra‐articular hyaluronan (Synvisc®) to reduce pain and improve function in people with hallux limitus.Methods: One hundred and fifty community‐dwelling men and women aged 18 years and over with hallux limitus (who satisfy inclusion and exclusion criteria) will be recruited.Participants will be randomised, using a computer‐generated random number sequence, to receive a single intra‐articular injection of up to 1 ml hyaluronan (Synvisc®) or sterile saline (placebo) into the first MPJ. The injections will be performed by an interventional radiologist using fluoroscopy to ensure accurate deposition of the hyaluronan in the joint. Participants will be given the option of a second and final intra‐articular injection (of Synvisc® or sterile saline according to the treatment group they are in) either 1 or 3 months post‐treatment if there is no improvement in pain and the participant has not experienced severe adverse effects after the first injection. The primary outcome measures will be the pain and function subscales of the Foot Health Status Questionnaire. The secondary outcome measures will be pain at the first MPJ (during walking and at rest), stiffness at the first MPJ, passive non‐weightbearing dorsiflexion of the first MPJ, plantar flexion strength of the toe‐flexors of the hallux, global satisfaction with the treatment, health‐related quality of life (assessed using the Short‐Form‐36 version two questionnaire), magnitude of symptom change, use of pain‐relieving medication and changes in dynamic plantar pressure distribution (maximum force and peak pressure) during walking. Data will be collected at baseline, then 1, 3 and 6 months post‐treatment. Data will be analysed using the intention to treat principle.Discussion: This study is the first randomised placebo controlled trial to evaluate the efficacy of intra‐articular hyaluronan (Synvisc®) for the treatment of osteoarthritis of the first MPJ (hallux limitus). The study has been pragmatically designed to ensure that the study findings can be implemented into clinical practice if this form of treatment is found to be an effective treatment strategy.Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12607000654459


  • Large aggregating and small leucine‐rich proteoglycans are degraded by different pathways and at different rates in tendon

    by Tom Samiric, Mirna Z. Ilic, Christopher J. Handley

    This work investigated the kinetics of catabolism and the catabolic fate of the newly synthesized 35S‐labelled proteoglycans present in explant cultures of tendon. Tissue from the proximal region of bovine deep flexor tendon was incubated with [35S]sulfate for 6 h and then placed in explant cultures for periods of up to 15 days. The amount of radiolabel associated with proteoglycans and free [35S]sulfate lost to the medium and retained in the matrix was determined for each day in culture. It was shown that the rate of catabolism of radiolabelled small proteoglycans (decorin and biglycan) was significantly slower (T½ > 20 days) compared with the radiolabelled large proteoglycans (aggrecan and versican) that were rapidly lost from the tissue (T½ ≈ 2 days). Both the small and large newly synthesized proteoglycans were lost from the matrix with either intact or proteolytically modified core proteins. When explant cultures of tendon were maintained either at 4 °C or in the presence of the lysosomotrophic agent ammonium chloride, inhibition of the cellular catabolic pathway for small proteoglycans was demonstrated indicating the involvement of cellular activity and lysosomes in the catabolism of small proteoglycans. It was estimated from these studies that approximately 60% of the radiolabelled small proteoglycans that were lost from the tissue were degraded by the intracellular pathway present in tendon cells. This work shows that the pathways of catabolism for large aggregating and small leucine‐rich proteoglycans are different in tendon and this may reflect the roles that these two populations of proteoglycans play in the maintenance of the extracellular matrix of tendon.


  • Distribution of newly synthesized aggrecan in explant cultures of bovine cartilage treated with retinoic acid

    by Christopher J Handley, Gavin M Winter, Mirna Z Ilic, Jacqueline M Ross, C Anthony Poole, H Clem Robinson


  • Catabolism of newly synthesized decorin by explant cultures of bovine ligament

    by Ann D. Winter, Margaret A. Campbell, H.CLem Robinson, Christopher J. Handley


  • Metabolic processing of newly synthesized link protein in bovine articular cartilage explant cultures

    by Angus M. Tester, Mirna Z. Ilic, H.Clem Robinson, Christopher J. Handley


  • Identification of Distinct Metabolic Pools of Aggrecan and Their Relationship to Type VI Collagen in the Chondrons of Mature Bovine Articular Cartilage Explants

    by Gavin M. Winter, C. Anthony Poole, Mirna Z. Ilic, Jacqueline M. Ross, H. Clem Robinson, Christopher J. Handley

    The metabolism and distribution of newly synthesized aggrecan present in the extracellular matrix of intact explant cultures of mature articular cartilage was investigated with respect to type VI collagen-stained chondrons. Using biochemical, autoradiographical and novel confocal immunohistochemical techniques it was shown that aggrecan exists as a number of distinct pools that are located within the extracellular matrix of the tissue. The first was identified as a pool of high specific radioactivity, much of which appeared in the medium one day after incubation with radiolabeled sulfate. Of the radiolabeled aggrecan remaining within the extracellular matrix, three pools were differentiated on the basis of time and location within the extracellular matrix. One pool was resident within the pericellular microenvironment associated with the chondron, one migrated into the territorial matrix adjacent to the chondron and one was sequestered long term in the interterritorial matrix. Analysis of the kinetics of loss of radiolabeled aggrecan macromolecules present in the region of matrix defined by the chondron suggests that this pool rapidly turns over and is a precursor to the pools of aggrecan present in the territorial and interterritorial matrix. There were marked differences in the distribution of newly synthesized aggrecan present in these regions of the extracellular matrix in explant cultures maintained with or without fetal calf serum. In the absence of serum, more of the newly synthesized aggrecan moved into the territorial and interterritorial matrix indicating that the presence of serum in the culture medium influenced the tissue distribution of aggrecan. This work indicates that the pericellular microenvironment of the chondron plays an important role in the retention and maturation of aggrecan prior to the sequestration of aggrecan complexes into the functional load bearing matrices of adult articular cartilage.